에 대한 최신 뉴스 Spear Alpha ETF (NASDAQ:SPRX)

Technology

Utilities

Consumer Cyclical

Energy

Industrials

Basic Materials

Spear Funds

The Fund is an actively managed exchange-traded fund that invests primarily in equity securities, including common stock or American depositary receipts, of companies that Spear Advisors LLC, the Funds investment adviser, believes are poised to benefit from breakthrough innovation in industrial technology. For purposes of the Funds investments, the Adviser defines innovation in industrial technology as those technological developments that are transforming or have the potential to transform the industrial sector.

NVIDIA Corporation

Zscaler  Inc .

Advanced Micro Devices Inc

Cloudflare, Inc. (class A)

Snowflake Inc

Shopify Inc Class A

Datadog Inc

SentinelOne Inc

Amphenol Corp

Marvell Technology Inc

Tesla, Inc.

Rigetti Computing Inc

Ionq, Inc. Pipe

Vistra Corp

Arista Networks Inc.

Astera Labs

Constellation Energy Corp

Ge Vernova Inc

Spear Alpha ETF

AMD stock

Equities

News

Markets

Movers

General

AOTG

SPRX

Simplify Volt RoboCar Disruption and Tech ETF

VCAR

어드밴스드 마이크로 디바이시스(NASDAQ:AMD)는 도난당한 AMD 데이터를 소유하고 있다고 주장하는 사이버 범죄 조직을 인지하고 있음을 확인했다.

벤징가(Benzinga)의 질문에 대해 AMD는 &#34;훔친 AMD 데이터를 소유하고 있다고 주장하는 사이버 범죄 조직을 알고 있다. 우리는 법집행관들 및 제3자 호스팅 파트너와 긴밀히 협력하여 주장과 데이터의 중요성을 조사하고 있다.&#34;

AMD 사이버 공격? 해커가 도난된 데이터를 판매한다고 주장, 회사는 법 집행 당국과 협조

Macquarie analyst Chad Beynon maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Outperform and lowers the price target from $58 to $52.

Price Target

Analyst Ratings

Macquarie Maintains Outperform on Las Vegas Sands, Lowers Price Target to $52

Trial achieves positive results in the treatment of persistent atrial fibrillation
MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ --&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) today announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the FARAPULSE&#x2122; Pulsed Field Ablation (PFA) System&#x2A; and adjunctive use of the FARAPOINT&#x2122; PFA Catheter in patients with persistent atrial fibrillation (AF). &nbsp;Key findings from the study were presented at the second annual PFA Live Case Summit in San Diego and simultaneously published in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4411722-1&amp;h=2061933693&amp;u=https%3A%2F%2Fwww.ahajournals.org%2Fdoi%2F10.1161%2FCIRCULATIONAHA.125.074485&amp;a=Circulation">Circulation</a>.
Persistent AF, which accounts for approximately 25%1 of all AF cases, is an abnormal, rapid heartbeat that lasts for at least seven days in a row and can lead to complications such as blood clots, stroke and heart failure. The second phase of the ADVANTAGE AF trial studied the FARAWAVE&#x2122; PFA Catheter for both pulmonary vein isolation (PVI) and posterior wall ablation (PWA) and the FARAPOINT PFA Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter (AFL), a type of heart rhythm disorder. All patients in the trial were continuously monitored after their procedure with the LUX-Dx&#x2122; Insertable Cardiac Monitor (ICM) System, which is designed to detect recurrence of cardiac arrhythmias and assess AF burden. Findings from the trial met all pre-specified safety and effectiveness endpoints and demonstrated:
<ul>
<li>73.4% freedom from AF, AFL and atrial tachycardia (AT), which exceeded the performance goal of 40% or higher.</li>
<li>A safety event rate of 2.4% and no reports of pulmonary vein stenosis, atrio-esophageal fistula or phrenic nerve palsy which met the performance goal of 12% or lower.</li>
<li>81.0% freedom from symptomatic documented AF recurrence, which is defined as arrhythmia, clinical intervention or use of escalated or new Class I/III anti-arrhythmic drugs.</li>
<li>71.6% of patients had virtually no atrial arrhythmia (AA) burden, in which data shows lower AA burden can be associated with fewer clinical interventions and improvements in quality of life and 52% of patients had no residual AA events after the blanking period.</li>
<li>96.4% of patients treated with the FARAPOINT PFA Catheter had no recurrence of AFL.</li>
</ul>
Boston Scientific anticipates U.S. Food and Drug Administration approval to expand the instructions for use labeling for the FARAPULSE PFA System to include persistent AF as well as European and U.S. regulatory approvals for the FARAPOINT PFA Catheter in the second half of 2025.
 &nbsp;

Boston Scientific Says Second Phase Of ADVANTAGE AF Clinical Trial Of FARAPULSE Pulsed Field Ablation System Meets Primary Safety And Efficacy Endpoints

Wall Street analysts rerated Imax Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) after its <a href="https://www.benzinga.com/pressreleases/25/04/b44964131/imax-corporation-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">first-quarter results</a> Wednesday. 
Rosenblatt analyst Steve Frankel maintained Imax with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/IMAX/analyst-ratings" rel="noreferrer noopener">$35&nbsp;price target</a> Thursday.
JP Morgan analyst David Karnovsky reiterated a Neutral rating on Imax with a price target of $26 Thursday.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/entertainment/25/04/44752206/strong-slate-premium-push-fuel-imax-forecast-upgrades-says-analyst" rel="noreferrer noopener">Strong Slate, Premium Push Fuel IMAX Forecast Upgrades, Says Analyst</a>
Rosenblatt: Fueled by the runaway success of Ne Zha 2, Imax reported $86.7 million in revenue (+9.5% Y/Y) and $37.0 million in adjusted EBITDA, well ahead of both Frankel&#8217;s $82.8 million and $26.9 million and the consensus of $84.0 million and $27.4 million. 
The quarter also featured the signing of 95 new screens (and over 100 so far this year), reflecting the industry&#8217;s anticipation of a strong film slate in 2025 and 2026, as well as consumers&#8217; growing preference for premium cinema experiences, especially IMAX.
The second quarter is off to a strong start with A Minecraft Movie and Sinners, where Imax accounted for 18% of the film&#8217;s opening weekend on a global basis. From now until August, every Imax Hollywood release is part of the Filmed for Imax program, which sets the stage for material to over-index and drive the box office upside. Importantly, it is not just about Hollywood. 
This year is set to be a record period for local language films, boosted by Ne Zha 2 and other titles in China, Japan, and India that are expected to perform well. In 2019, local language represented 12% of GBO, rising to 21% in 2023. In the first quarter, the local language was 68%. 
Imax continues to command a growing portion of the market, accounting for 3.5% of the global box office on less than 1% of the screens. In China, the company&#8217;s share hit a record 5.4% in the first quarter, compared to 3.8% the previous year. Domestically, Imax accounted for 3.6% of the market in the first quarter, down from the 4.5% share it had in the previous year&#8217;s Dune 2.
Frankel projected second-quarter revenue of $83.95 million and adjusted EPS of $0.19.
JP Morgan: Imax shares were up ~5% post-market close after reporting first-quarter results. Revenue and adjusted EBITDA were $87 million and $37 million, compared to JP Morgan estimates of $85 million and $32 million. Content Solutions&#8217; gross profit was a beat on margin, with management citing the greater contribution of local China content and a more efficient marketing strategy in the region that leveraged social channels.
At Tech Products and Services, STL/ hybrid installs of 13 compared to the 5 Karnovsky modeled and helped drive a beat on gross margin. Free cash flow in the first quarter, net of growth capex, was -$7 million, an improvement from -$18 million in the year prior. 
Imax disclosed system signings of 95 in the first quarter, with the increase Y/Y partly reflective of a recently <a href="https://www.benzinga.com/news/contracts/25/04/44603254/amc-expands-premium-movie-experience-with-imax-laser-upgrades-in-landmark-deal" target="_blank" rel="noreferrer noopener">announced agreement with</a> AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>). First-quarter box office indexing was reported at 3.5% globally and 5.4% for China, a record. Karnovsky estimates that the US was at 3.6% (down from 5.9% in the first quarter of 2024, which featured Dune 2).
The company maintained guidance for 2025. Management did state that the results were tracking ahead of expectations, and a reiteration of the outlook after only a quarter was not a surprise. On the topic of China, CEO Richard Gelfond commented that a &#8216;moderate&#8217; reduction in film imports would target movies with limited box office potential, not the kind the company distributes. 
Karnovsky noted the wording of the China Film Administration&#8217;s recent announcement, which stated that it would consider market demand in its decision-making. Management also asserted there had been no reduction in activity among Chinese exhibitors and their interest in Imax, but rather that this had increased on the back of Ne Zha. 
Overall, Karnovsky is incrementally positive following the solid print and commentary on China, which should ease investor concerns to a degree, even as the analyst expects some near-term risk to persist, given the volatility of the situation.
Karnovsky projected second-quarter revenue of $90 million and adjusted EPS of $0.05.
Price Action: IMAX stock is down 2.66% at $23.46 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44978343/comcast-hit-hard-by-subscriber-exodus-nearly-630000-customers-gone-in-q1" target="_blank" rel="noreferrer noopener">Comcast Hit Hard By Subscriber Exodus, Nearly 630,000 Customers Gone In Q1</a></li>
</ul>
Photo: Shutterstock

Earnings

Entertainment

IMAX

Imax Wins Analyst Praise On Strong Film Slate, But China Market Volatility Raises Concerns

Guardant Health, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) to support the development and commercialization of Pfizer&#8217;s oncology portfolio using the Guardant Infinity smart <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">liquid biopsy platform</a>.
Under the multi-year collaboration agreement, Guardant and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44976810/guardant-health-announces-strategic-collaboration-with-pfizer-to-support-development-and-commercia" rel="noreferrer noopener">Pfizer aim to</a>:
<ul>
<li>Utilize Guardant&#8217;s portfolio of liquid biopsy tests in Pfizer&#8217;s global clinical studies.</li>
<li>Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44259889/medicare-to-reimburse-guardant-healths-shield-colorectal-cancer-test-at-1495-starting-april-2025-analyst-sees-as-positive-development" rel="noreferrer noopener">Medicare To Reimburse Guardant Health&#8217;s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue</a>
The collaboration will also allow Pfizer to access Guardant&#8217;s liquid biopsy tests in China for its global clinical trials, which include China cohorts.
In July 2022, Guardant announced a strategic partnership with Adicon Holdings Limited, an independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China.
In January, Guardant Health announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44919683/guardant-health-to-present-data-highlighting-advances-in-multi-cancer-detection-and-liquid-and-tis" rel="noreferrer noopener">curative intent therapy</a>.
Guardant Reveal, which runs on Guardant&#8217;s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal residual disease (MRD). This test predicts cancer recurrence, helping to guide clinical decisions after surgery or chemotherapy.
Price Action: GH stock is up 2.59% at $46.82 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44992019/edwards-lifesciences-stock-earns-analyst-upgrade-as-growth-outlook-brightens" target="_blank" rel="noreferrer noopener">Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

Health Care

Contracts

Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform

Editor's Note: This article has been updated to reflect that Alphabet will report first-quarter earnings on Thursday.
Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will be reporting its first-quarter earnings on Thursday. Wall Street expects $2.02 in EPS and $88.87 billion in revenues as the company reports <a href="https://www.benzinga.com/calendars/earnings?tickers=GOOGL">after market hours</a>.
The stock is down 2.38% over the past year and a steeper 17.99% year-to-date.
Let's look at what the charts indicate for Alphabet stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/markets/25/04/44971069/google-to-remote-workers-return-to-office-3-days-a-week-or-take-a-buyout-report">Google To Remote Workers — Return To Office 3 Days A Week Or Take A Buyout: Report</a>
<h2 class="wp-block-heading">Alphabet Stock In A Tug-Of-War Ahead Of Q1 Earnings</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24091753/Screenshot-2025-04-24-at-6.37.54-PM.png" alt="" class="wp-image-886625" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24091753/Screenshot-2025-04-24-at-6.37.54-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24091753/Screenshot-2025-04-24-at-6.37.54-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0424" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, Alphabet is caught in a tug-of-war between short-term bullish signals and a longer-term bearish downtrend. The stock, at $155.30, is trading just above its eight-day and 20-day simple moving averages (SMAs) of $153.71 and $153.57, respectively—both bullish indicators suggesting that buyers are stepping in at the margins ahead of earnings.
But the deeper trend tells a more cautious story. Alphabet remains firmly below its 50-day and 200-day SMAs of $164.54 and $172.41, respectively, which implies that broader sentiment hasn't turned around yet.
In addition, the MACD (Moving Average Convergence Divergence) indicator is sitting at a negative 3.25, reinforcing a bearish outlook for now. The RSI (Relative Strength Index) of 47.63 puts it in a neutral zone &#8211; not oversold, but not hot either.
For investors, this sets up a high-stakes earnings event. A solid beat and confident commentary on the $75 billion AI infrastructure play could catalyze a reversal in longer-term trends. However, failing to address legal overhangs &#8211; especially the risk of restructuring its advertising empire after an antitrust ruling &#8211; might deepen the selloff.
<h2 class="wp-block-heading">Alphabet Analysts See 24% Upside</h2>
Ratings &amp; Consensus Estimates: The <a href="https://www.benzinga.com/quote/GOOGL/analyst-ratings">consensus analyst rating</a> for Alphabet stock is currently a Buy, with a price target of $197.83. The three most recent analyst updates, from Stifel, RBC Capital, and Morgan Stanley, give an average price target of $192.33, suggesting an implied 23.85% upside from current levels.
Price Action: Alphabet stock was up 2% to $160.96 at the time of publication Thursday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/04/44977897/exclusive-nvidia-alphabet-microsoft-amazon-meta-now-in-the-bargain-bin-after-being-heavily-sold-off-says-expert" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Nvidia, Alphabet, Microsoft, Amazon, Meta &#8211; Now In The Bargain Bin After Being &#8216;Heavily Sold Off&#8217;, Says Expert</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

Tech

Trading Ideas

GOOG

GOOGL

Alphabet Walks A Tightrope Into Q1 Earnings: Bearish Charts, Bullish Expectations (CORRECTED)

Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares surged 23% to $3.16 Thursday afternoon alongside the broader semiconductor sector, benefiting from a favorable mix of strong economic data and renewed optimism around <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">U.S.-China trade relations</a>. 
What To Know: As a manufacturer of silicon carbide semiconductors used in electric vehicles and industrial applications, Wolfspeed is a player in the global energy transition and high-efficiency electronics market.
One catalyst for Thursday&#8217;s rally was a <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44979310/durable-goods-orders-jump-9-2-in-march-but-one-category-tells-the-real-story">9.2% spike</a> in U.S. durable goods orders in March, the strongest in over eight months, reflecting a surge in capital goods excluding defense and aircraft—a proxy for business investment. 
Despite weakness in traditional electronics and computer segments, the surge in high-value manufacturing suggests potential rising demand for Wolfspeed's next-gen semiconductor materials.
Adding to momentum, hopes for easing tensions between the U.S. and China and the potential for tariff exceptions on tech components could be buoying sentiment.
With the Nasdaq-100 up 2.5%, investors on Thursday rotated into <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">high-growth tech names</a>, lifting Wolfspeed as part of the semiconductor rally.
Read Also: <a href="https://www.benzinga.com/25/04/44988897/china-trade-war-4-big-brand-stocks-that-will-suffer-most">China Trade War: 4 Big-Brand Stocks That Will Suffer Most</a>
<h2 class="wp-block-heading">How To Buy WOLF Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Wolfspeed&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WOLF has a 52-week high of $30.86 and a 52-week low of $2.06.

WOLF

Wolfspeed (WOLF) Stock Is Up 23% Thursday: What's Going On?

<a href="https://www.reuters.com/world/us/us-justice-dept-grant-cuts-valued-811-million-people-familiar-say-2025-04-24/" title="https://www.reuters.com/world/us/us-justice-dept-grant-cuts-valued-811-million-people-familiar-say-2025-04-24/">https://www.reuters.com/world/us/us-justice-dept-grant-cuts-valued-811-million-people-familiar-say-2025-04-24/</a>

'Exclusive: US Justice Dept Grant Cuts Valued At $811 Million, People Familiar Say' - Reuters News

DA Davidson analyst Brian Holland upgraded Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) from Neutral to Buy on Thursday, <a href="https://www.benzinga.com/quote/UTZ/analyst-ratings" target="_blank" rel="noreferrer noopener">maintaining the price forecast of $16.</a>
The analyst sees a compelling &#8220;risk-reward&#8221; setup for Utz Brands despite broader challenges in the food sector.
Holland highlights several supportive factors, including a firming position in the salty snacks category, which benefits from reduced promotional pressure and Utz Brands&#8217; strong performance in non-tracked retail channels.
Additionally, the company has exceeded expectations in transforming its supply chain, potentially setting the stage for upward earnings revisions if its recent market share gains continue.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44988897/china-trade-war-4-big-brand-stocks-that-will-suffer-most" rel="noreferrer noopener">China Trade War: 4 Big-Brand Stocks That Will Suffer Most</a>
The analyst also notes that, aside from names like Freshpet, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) and SunOpta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>), no other food stock is currently trading at &#8220;a wider relative valuation gap.&#8221;
The company released<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44861060/utz-appoints-william-j-kelley-jr-as-chief-financial-officer" rel="noreferrer noopener"> 1Q25 preliminary results released last week.</a>
Although overall sales in the salty snack category have remained weak due to inflation-driven volume pressure, growing health consciousness, and possible impacts from GLP-1 usage, the analyst notes that Utz Brands has steadily gained market share.
This modest but consistent share growth has been driven by expanded distribution, increased marketing efforts, and product innovation targeting largely untapped markets—particularly in regions that account for over 60% of salty snack sales.
While competitive promotions, especially from dominant players like Frito-Lay, created challenges through 2024, the lack of sustained volume gains from those promos led to a market reset, the analyst writes.
Price Action: Utz shares are trading higher by 1.61% to $13.60 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44989420/vinfast-auto-maintains-ev-delivery-outlook-amid-macro-uncertainty-despite-q4-margin-drag" target="_blank" rel="noreferrer noopener">VinFast Auto Maintains EV Delivery Outlook Amid Macro Uncertainty Despite Q4 Margin Drag</a></li>
</ul>
Image: Shutterstock

FRPT

STKL

Utz Brands Gets Analyst Upgrade As Salty Snacks Gain Traction, Promotions Ease

Penumbra Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) stock is trading higher after the company reported better-than-expected&nbsp;first-quarter 2025 earnings and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44964153/penumbra-inc-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">reaffirmed the 2025 forecast</a>.
The medical device company reported:
<ul>
<li>Sales of $324.1 million, up 16.3% year over year (+16.9% in constant currency) and beating the consensus of $315.66 million.</li>
<li>Adjusted EPS of 83 cents, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of 67 cents</a>.</li>
</ul>
Revenue from global thrombectomy products grew to&nbsp;$226.5&nbsp;million in the first quarter of 2025, an increase of 20.7%, or 21.2%, in constant currency.
<ul>
<li>U.S. Thrombectomy revenue of&nbsp;$187.9 million increased 25.0% year over year.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44977669/pepsico-ceo-warns-of-tariffs-led-increase-in-supply-chain-costs-cuts-annual-profit-outlook" rel="noreferrer noopener">PepsiCo CEO Warns Of Tariffs Led &#8216;Increase In Supply Chain Costs,&#8217; Cuts Annual Profit Outlook</a>
Revenue from global embolization and access products grew 7.3% of 8.1% in constant currency to&nbsp;$97.6&nbsp;million.
<ul>
<li>U.S. embolization and access products revenue increased 16.2% to 68.97 million</li>
</ul>
Operating income reached $40.4 million. Q1 net income was $39.2 million and adjusted EBITDA of $59.6 million, with 12.1% and 18.4% margins, respectively.
Guidance: Penumbra reaffirms its fiscal year 202 sales guidance of $1.34 billion to $1.36 billion, versus the consensus of $1.35 billion.
<ul>
<li>The company is increasing guidance for the U.S. Thrombectomy franchise growth to 20% to 21% year over year <a href="https://www.benzinga.com/25/02/43829643/stroke-device-maker-penumbra-stock-surges-on-earnings-beat-upbeat-2025-outlook-analysts-boost-price-forecasts" target="_blank" rel="noreferrer noopener">from 19% to 20%</a>.</li>
<li>It reaffirms guidance for gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to 13%-14% of revenue for 2025.</li>
</ul>
William Blair notes that since the company manufactures in the U.S. and gets 75% of its raw materials domestically, it expects little impact from tariffs this year. Also, with nearly 80% of its revenue coming from the U.S., the company has left out a $5 million contribution from China in its full-year outlook.
&#8220;We believe Penumbra is one of the most well-insulated companies from ongoing tariff dynamics across our coverage,&#8221; analyst Margaret Kaczor Andrew writes.
William Blair maintains an Outperform rating for Penumbra stock.
&#8220;Looking at the momentum thus far and management's thoughtful approach to guidance, we see further room for share upside as the company executes on its four-pronged strategy,&#8221; analyst Andrew adds.
Analyst Reaction:
<ul>
<li>Stifel maintains a Buy rating on Penumbra, raising the price target from $301 to $318.</li>
<li>Truist Securities maintains a Buy rating on Penumbra, raising the price target from $315 to $330.</li>
<li>Wells Fargo maintains a rating of Penumbra as Overweight, raising the price target from $305 to $315.</li>
<li>Baird maintains Penumbra with an Outperform, raising the price target from $316 to $325.</li>
<li>UBS maintains a Buy rating on Penumbra and raises the price target from $320 to $330.</li>
</ul>
Price Action: PEN stock is up 6.37% at $296.53 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44976464/alaska-air-hit-by-demand-dip-in-q1-loss-skips-fy25-guidance-update-amid-uncertainty" target="_blank" rel="noreferrer noopener">Alaska Air Hit By Demand Softness In Q1, Skips Annual Outlook Citing Macro Uncertainty</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Guidance

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

On Wednesday, ResMed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) reported that third-quarter adjusted EPS was $2.37, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $2.36</a>.
Quarterly sales increased 8% year over year to $1.29 billion, which aligns<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener"> with estimates</a>.
Sales increased 9% on a constant currency basis. The company credited increased demand for sleep devices and growth within the <a href="https://www.benzinga.com/pressreleases/25/04/g44964087/resmed-inc-announces-results-for-the-third-quarter-of-fiscal-year-2025" target="_blank" rel="noreferrer noopener">Residential Care Software business</a>. In addition:
<ul>
<li>Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9%.</li>
<li>Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 8% on a constant currency basis.</li>
<li>Residential Care Software revenue increased by 10% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44966369/novavaxs-covid-19-vaccine-nears-fda-full-approval-stock-jumps" rel="noreferrer noopener">Novavax&#8217;s COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps</a>
Gross margin increased by 140 basis points to 59.3%, mainly due to manufacturing and logistics efficiencies and favorable shifts in product mix, partially offset by unfavorable foreign currency movements. Non-GAAP&nbsp;gross margin increased by 140 basis points to 59.9%.
Adjusted operating income increased 13% to $444.6 million. Adjusted net income increased by 11% to $348.5 million.
William Bliar writes that on tariffs, management confirmed with federal government officials earlier this month that its products are exempt, subject to the Nairobi Protocol, which the company had filed and was approved for in 2009.
<ul>
<li>The Nairobi Protocol is an international agreement allowing duty-free importation of products designed for the use of people with disabilities, which has historically included medical devices.</li>
<li>Though some component costs may not be exempt, management characterized these as having a minimal to immaterial impact.</li>
<li>Analyst Margaret Kaczor Andrew writes, &#8220;This is welcome news, with ResMed the first company this earnings cycle in our coverage universe to report as much.&#8221;</li>
</ul>
Analyst Reaction:
<ul>
<li>Keybanc maintains ResMed with an Overweight, raising the price <a href="https://www.benzinga.com/quote/RMD/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $269 to $274</a>.</li>
<li>Piper Sandler maintains ResMed with a Neutral, lowering the price target from $260 to $248.</li>
<li>JP Morgan maintains ResMed with an Overweight, raising the price target from $286 to $290.</li>
</ul>
Price Action: ResMed stock is up 11% at $238.10 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44979300/centerpoint-slips-after-q1-results-reflect-cost-pressures-offset-by-favorable-weather" target="_blank" rel="noreferrer noopener">CenterPoint Slips After Q1 Results Reflect Cost Pressures, Offset By Favorable Weather</a></li>
</ul>

ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

SoundHound AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares climbed 7.0% to $9.37 Thursday afternoon amid a broader surge in technology stocks, fueled by strong U.S. durable goods data and signs of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">easing U.S.-China trade tensions</a>.
What To Know: The voice AI company, known for its advanced speech recognition and natural language processing technology, benefited from investor optimism across the tech sector, particularly as markets <a href="https://www.benzinga.com/25/04/44982688/alphabet-q1-earnings-preview-google-parent-stock-at-fork-in-the-road-while-antitrust-concerns-remain">anticipate strong earnings</a> from Alphabet Inc after the bell.
SoundHound&#8217;s gains align with Thursday&#8217;s bullish sentiment around AI and software companies, with the Nasdaq-100 jumping 2.5% and tech outperforming other sectors. 
Positive corporate earnings and guidance from tech peers like ServiceNow also buoyed expectations for companies like SoundHound, which has been expanding its partnerships in automotive, hospitality and smart device markets. 
Read Also: <a href="http://Why Odyssey Marine Exploration (OMEX) Stock Is Exploding Higher">Why Odyssey Marine Exploration Stock Is Exploding Higher</a>
<h2 class="wp-block-heading">How To Buy SOUN Stock</h2>
By now you're likely curious about how to participate in the market for SoundHound AI &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of SoundHound AI, which is trading at $9.37 as of publishing time, $100 would buy you 10.67 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOUN has a 52-week high of $24.98 and a 52-week low of $3.82.

SOUN

What's Going On With SoundHound AI (SOUN) Stock?

When markets become moody, alternating between panic and euphoria, dividend stocks tend to offer a rare type of peace: predictability. For decades, they&#8217;ve provided a mix of income and stability that even the most flashy growth stocks can&#8217;t. And in that dividend-rich jungle, the Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) is an <a href="https://www.benzinga.com/etfs">ETF kingpin</a>.
Let's talk receipts. Since its launch in 2011, SCHD has delivered total returns of 203%. That's not just "good-for-an-ETF" good—that's "maybe-I-should-rethink-my-investment-strategy" good. Along the way, it has consistently raised its dividend, even as markets fluctuated through pandemics, inflation tantrums and meme-stock mania.
Also Read: <a href="https://www.benzinga.com/25/04/44843179/the-dividend-etf-that-just-woke-up-and-why-investors-are-watching-closely">The Dividend ETF That Just Woke Up And Why Investors Are Watching Closely</a>
What's the secret sauce? SCHD holds a curated lineup of 100 high-quality, dividend-paying U.S. stocks. We're talking Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)—dividend legends, not one-hit wonders.
SCHD&#8217;s SEC 30-day yield is at 4.01%. That&#8217;s high. 
For perspective, as of 2015, <a href="https://www.benzinga.com/quote/SCHD/dividends">SCHD&#8217;s typical yield has stuck around 3%</a>, and before 2022, it rarely broke through that. Yet here we sit, with a yield comparable to high-yield savings accounts—albeit many times more intriguing in the near future. Why? Because HYSAs don&#8217;t have to contend with compounding. SCHD&#8217;s does.
The Catch
Well, like everything in life (and finance), there is a trade-off. SCHD&#8217;s price has been hit in 2025, down close to 6% year-to-date and 9.5% in the last six months. Its increasing yield is partly due to declining prices. But long-term investors look at that as a signal to buy. Particularly those in pursuit of not only current yield but yield on cost (return/yield based on original cost and not current market price).
Projecting forward, SCHD could offer a yield on cost of over 14% in 10 years, assuming its current growth pace holds. The math makes a compelling case for SCHD as a long-term income generator.
Low Fees, High Value
At a mere 0.06% expense ratio, SCHD isn&#8217;t only generous with dividends, it&#8217;s also notoriously cheap on fees. That leaves more cash where it belongs: in your wallet.
3 Other Dividend ETFs Worth Watching
If SCHD is the class valedictorian of dividend ETFs, here are two other top-of-the-class performers that deserve honorary degrees:
Vanguard High Dividend Yield ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYM#NYSE">VYM</a>)
VYM targets U.S. businesses with higher-than-average dividend payouts and owns 589 holdings, so it&#8217;s more diversified than SCHD. Its current 30-day SEC yield is approximately 2.67%, and it has a bargain-basement expense ratio of only 0.06%. 
iShares Select Dividend ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVY#NASDAQ">DVY</a>)
DVY goes the old-fashioned route, with a preference for utilities and industrials—your grandfather&#8217;s portfolio, but without the &#8220;old&#8221; part. It yields more than 3.7% and invests in stocks with a solid five-year history of paying dividends. With more than 100 holdings, it&#8217;s slightly more focused than VYM but offers a different sector bias that can complement a dividend portfolio. Expense ratio is 0.38%.
Bottom Line
While SCHD remains a standout stock for dividend growth, including VYM and DVY can add valuable diversity to your income strategy. Each provides something distinct in the way of dividend exposure—either more yield, defensive sector exposure, or longer-term consistency.
So if your portfolio needs a little less drama and a little more cash, consider making these dividend ETFs a permanent fixture at the table. Slow and steady wins the race—particularly when it pays you every quarter.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/specialty-etfs/25/04/44979728/intel-cuts-staff-etfs-brace-for-blow-q1-earnings">Intel Slashes Staff Ahead Of Q1 Earnings, ETFs Brace For Impact</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

ETFs

iShares Dow Jones Select Dividend Index Fund

SCHD

SCHD Is Down, But Its Dividend Is Up And These 2 ETFs Are Quietly Catching Up

<a href="https://www.thetimes.com/business-money/economics/article/blackrock-ceo-larry-fink-im-buying-up-undervalued-uk-assets-v2jrxpbkb" title="https://www.thetimes.com/business-money/economics/article/blackrock-ceo-larry-fink-im-buying-up-undervalued-uk-assets-v2jrxpbkb">https://www.thetimes.com/business-money/economics/article/blackrock-ceo-larry-fink-im-buying-up-undervalued-uk-assets-v2jrxpbkb</a>

Macro Economic Events

Politics

Global

Economics

"BlackRock CEO Larry Fink: I'm buying up 'undervalued' UK assets; Larry Fink praised the government's pro-growth agenda and said many British stocks were at 'too deep' a discount" - The Times

Shares of Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) are trading higher Thursday. The company selected Hesai Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>)&#8217;s AT128 lidar sensors as the primary lidar system for its new seventh-<a href="https://www.benzinga.com/25/04/44985457/texas-instruments-posts-better-than-expected-results-joins-community-health-systems-hasbro-servicenow-resmed-and-other-big-stocks-moving-higher-on-thursday">generation Robotaxi fleet.</a>
What To Know: The two companies made the announcement at the Shanghai International Automobile Industry Exhibition, where Pony AI revealed its latest automotive-grade L4 autonomous driving platform. Each of the three new Robotaxi models will be equipped with four Hesai AT128 sensors.
The integration is intended to enable 360° obstacle detection and navigation in complex traffic conditions. The sensors are specifically engineered for scalable deployment in autonomous vehicles.
Pony AI claims its new system achieves a 70% reduction in component costs compared to earlier models and features a modular architecture for easier deployment across multiple vehicle platforms. The company also reports that its autonomous fleet has already logged over 500,000 hours of fully driverless operation, and claims a tenfold safety improvement over human drivers.
Price Action: Pony AI shares were up 34.5% at $7.30 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="539" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24143134/Screenshot-2025-04-24-at-14.31.17-1024x539.png" alt="" class="wp-image-887348" style="width:484px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24143134/Screenshot-2025-04-24-at-14.31.17-1024x539.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24143134/Screenshot-2025-04-24-at-14.31.17-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24143134/Screenshot-2025-04-24-at-14.31.17-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24143134/Screenshot-2025-04-24-at-14.31.17.png 1497w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">Wall Street Rally Extends Into Third Day: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image Via Shutterstock.

HSAI

PONY

Pony AI Shares Surge After Hesai Lidar Partnership Announcement: What's Going On?

WIIM

SWTX

SpringWorks Therapeutics shares are trading higher following a WSJ report indicating Germany's Merck is nearing a deal for the company.

<a href="https://www.wsj.com/business/deals/germanys-merck-nears-roughly-3-5-billion-deal-for-springworks-2c7258b9" title="https://www.wsj.com/business/deals/germanys-merck-nears-roughly-3-5-billion-deal-for-springworks-2c7258b9">https://www.wsj.com/business/deals/germanys-merck-nears-roughly-3-5-billion-deal-for-springworks-2c7258b9</a>

'Germany's Merck Nears Roughly $3.5 Billion Deal For SpringWorks; Merck And Springworks Have Agreed On A Price Close To $47 Per Share' - WSJ

Needham analyst Chris Pierce maintains Sonic Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) with a Buy and lowers the price target from $93 to $74.

Needham Maintains Buy on Sonic Automotive, Lowers Price Target to $74

Cantor Equity Partners shares are trading higher after entering into a business combination agreement with Twenty One Capital.

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $6 price target.

Reiteration

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $6 Price Target

<a href="https://www.theverge.com/news/655510/threads-com-web-app-domain" title="https://www.theverge.com/news/655510/threads-com-web-app-domain">https://www.theverge.com/news/655510/threads-com-web-app-domain</a>

"Threads' web app is moving from .net to .com; It's also testing a way for users to upload their following lists from other platforms, like X" - The Verge

어드밴스드 마이크로 디바이시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)는 도난당한 AMD 데이터를 소유하고 있다고 주장하는 사이버 범죄 조직을 인지하고 있음을 확인했다.
벤징가(Benzinga)의 질문에 대해 AMD는 "훔친 AMD 데이터를 소유하고 있다고 주장하는 사이버 범죄 조직을 알고 있다. 우리는 법집행관들 및 제3자 호스팅 파트너와 긴밀히 협력하여 주장과 데이터의 중요성을 조사하고 있다."
앞서 핵리드(HackRead)는 브리치 포럼즈(Breach Forums) 사이버 범죄 플랫폼의 악명 높은 해커이자 조정자인 인텔브로커(IntelBroker)에 의해 회사가 침해당했다고 <a href="https://www.benzinga.com/news/24/06/39255707/what-is-amd-stock-trading-lower-on-monday" rel="nofollow">보도</a>했다.
이 보도에 따르면 2024년 6월에 발생한 침입 혐의로 인해 다양한 범주에 걸쳐 상당한 양의 민감한 정보가 도난당한 것으로 알려졌다.
인텔브로커는 이 브리치 포럼즈에서 ROM, 펌웨어, 소스 코드, 속성 파일, 직원 및 고객 데이터베이스, 재무 정보, 향후 AMD 제품 계획 및 기술 사양을 포함하여 손상된 데이터에 액세스하는 방법을 자세히 설명했다.
이 주장된 침해에는 AMD 직원들의 전체 데이터베이스가 포함되어 사용자 ID, 직무, 이메일 주소, 고용 상태, 성과 이름, 회사 전화번호와 같은 민감한 개인 정보가 노출된 것으로 알려졌다.
이 보도에 따르면 이 해커는 중개자를 통해 거래가 촉진되는 XMR(모네로) 암호화폐 데이터를 독점적으로 판매하고 있다.
지난주 모건 스탠리의 분석가 조셉 무어(Joseph Moore)는 이 회사의 <a href="https://www.benzinga.com/news/24/06/39255707/what-is-amd-stock-trading-lower-on-monday" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">높은 가치를 지적</a>하면서 주식을 비중확대(Overweight)에서 동일 가중치(Equal-Weight)로 하향 조정했다.
<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="nofollow">Benzinga Pro</a>에 따르면 지난 1년 동안 AMD 주가는 30% 상승했다. 투자자들은 Spear Alpha ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>) 및 AOT Growth And Innovation ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOTG#NASDAQ">AOTG</a>)를 통해 AMD 주식에 노출될 수 있다.
별도의 릴리스에서 어드밴스드 마이크로 디바이시스와 보라고 테크놀로지스(VORAGO Technologies)는 VORAGO의 방사선 경화 마이크로컨트롤러가 <a href="https://www.benzinga.com/pressreleases/24/06/g39376291/vorago-rad-hard-mcu-enables-in-flight-reconfiguration-of-amd-space-grade-fpgas" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">AMD Space-Grade Kintex UltraScale FPGAs</a>를 재구성할 수 있다고 발표했다.
이번 협력을 통해 기존 AMD FPGA 기반 시스템에 방사선 경도를 추가하는 동시에 신뢰성과 유연성을 향상시켰다.
최근 어드밴스드 마이크로 디바이시스를 비롯한 반도체 칩 업체들은 역경 속에 계속되는 인공지능 열풍으로 각광을 받고 있다.
한편, 미국 정부는 중국의 러시아와의 무역 증가로 인해 모스크바가 <a href="https://www.benzinga.com/news/24/06/39284298/biden-administration-to-expand-sanctions-on-semiconductor-sales-to-russia-targeting-chinese-third-pa" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">계속해서 군대를 무장</a>할 수 있게 됐다는 점을 들어 중국과 중동에 이어 러시아에 대한 반도체 기술 수출 금지 조치를 연장하자고 제안했다.
중국에 대한 사전 제재는 이 제재를 준수하기 위해 반도체 회사들이 맞춤형으로 덜 효과적인 칩을 제조한 이후였다.
주가 움직임: 화요일 AMD의 주가는 2.38% 낮은 154.63달러로 마감했다.
면책 조항: AI 도구의 도움을 받아 이 콘텐츠의 일부가 작성되었으며 Benzinga 편집자들이 검토하고 발표했습니다.

Comments

Spear Alpha ETF

뉴스

에 대한 최신 뉴스 Spear Alpha ETF (NASDAQ:SPRX)

화요일, 6월 18, 2024

뉴스

파트너 / 기고자

벤징가 글로벌